Is afatinib a treatment option for brain metastases in patients with EGFR mutation-positive non-small cell lung cancer?

Ähnliche Einträge

• The effectiveness of EGFR-TKIs against brain metastases in EGFR mutation-positive non-small-cell lung cancer
  von: Bai, Hao, et al.
  Veröffentlicht: (2017)
• Afatinib: new treatment options for lung cancer with activating EGFR mutations
  von: M. V. Stepanchenko, et al.
  Veröffentlicht: (2015-12-01)
• Simultaneous targeting of MET overexpression in EGFR mutation-positive non-small cell lung cancer can increase the benefit of EGFR-TKI therapy?
  von: Kanemura, Hiroaki, et al.
  Veröffentlicht: (2020)
• Treatment of EGFR mutation–positive non–small cell lung cancer complicated by Trousseau syndrome with gefitinib followed by osimertinib: a case report
  von: Nonagase, Yoshikane, et al.
  Veröffentlicht: (2018)
• Response of Leptomeningeal Metastases in EGFR-Mutated Non-Small-Cell Lung Cancer to Afatinib in the Absence of Radiotherapy
  von: Llinás-Quintero, Néstor, et al.
  Veröffentlicht: (2019)